Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma

Cancer

Volumn 103, Issue 10, 2005, Pages 2109-2117

  Musolino, Antonino ^a   Perrone, Maria Antonietta ^a   Michiara, Maria ^a   Delnevo, Daniela ^b   Franciosi, Vittorio ^a   Di Blasio, Beatrice ^a   Ceci, Guido ^a   Camisa, Roberta ^a   Ardizzoni, Andrea ^a   Cocconi, Giorgio ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b Hospital of Piacenza   (Italy)

Author keywords

Bleomycin; Cisplatin; Disease recurrence; Ifosfamide; Lomustine (chloroethylnitrosourea CCNU ); Non Hodgkin lymphoma; Primary refractory; Vincristine

Indexed keywords

BLEOMYCIN; CISPLATIN; IFOSFAMIDE; LOMUSTINE; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RISK ASSESSMENT; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; L-LACTATE DEHYDROGENASE; LOMUSTINE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SURVIVAL RATE; VINCRISTINE;

EID: 18044396720     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21024     Document Type: Article

References (35)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
2. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117-122.
3. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169-1176.
4. Cabanillas F. Experience with ifosfamide combinations in malignant lymphomas. Semin Oncol. 1989;16(1 Suppl 3):78-81.
5. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995;6:609-611.
6. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3776-3785.
7. Hickish T, Roldan A, Cunningham D, et al. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer. 1993;68:599-604.
8. Palmieri G, Lauria R, Caponigro F, et al. Salvage chemotherapy for non Hodgkin's lymphoma of unfavourable histology with a combination of CCNU and vinblastine. Hematol Oncol. 1990;8:179-183.
9. Ruit JB, Lowenberg B, Hagenbeek A, et al. Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma. Semin Oncol. 1990;17:24-27.
10. Dorigo A, Mansberg R, Kwan YL. Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma. Eur J Haematol. 1993;50:37-40.
11. Papadopoulou MV, Epperly MW, Mainwarning A, et al. Potentiation of antineoplastic drugs in vitro and in vivo by DNA-intercalating bioreductive agents [abstract]. Proc Am Assoc Cancer Res. 1992;33:2619.
12. Durand J. Cisplatin and CCNU synergism in spheroid cell subpopulation. Br J Cancer. 1990;62:947-953.
13. Koldamova RP, Lefterov IM. Synergistic effect of CCNU and bleomycin on human lymphocytes exposed at late G1 and G2 states of the cell cycle. Mutat Res. 1991;260:265-269.
14. Dincol D, Icli F, Karaoguz H, et al. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma. Acta Oncol. 1995;34:937-940.
15. Hoogstraten B, Haas CD, Haut A, Talley RW, Rivkin S, Isaacs BL. CCNU and bleomycin in the treatment of cancer: a Southwest Oncology Group study. Med Pediatr Oncol. 1975;1:95-106.
16. Cohen SM, Ohnuma T, Ambinder EP, Holland JF. Lomustine, bleomycin, and cisplatin in patients with metastatic malignant melanoma. Cancer Treat Rep. 1986;70:688-689.
17. Harris NL, Jaffe ES, Diebald J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November, 1997. J Clin Oncol 1999;17:3835-3849.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
20. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
21. Cabanillas F, Hageimeister FB, McLaughlin P, et al. MIME combination chemotherapy for refractory or recurrent lymphomas. J Clin Oncol. 1987;5:407-412.
22. Freeman DH. Applied categorical data analysis. New York: Marcel Dekker, Inc., 1987.
23. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995;13:1734-1741.
24. Haim N, Ben-Shahar M, Faraggi D, Tsuri-Etzioni A, Levion M, Epelbaum R. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma. Cancer. 1997;80:1989-1996.
25. Armitage JO, Vose JM, Bierman PJ. Salvage therapy for patients with non-Hodgkin's lymphoma. Monogr Natl Cancer Inst. 1990;10:39-43.
26. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
27. Blay J, Gomez F, Sebban C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998;92:3562-3568.
28. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance of cure? J Clin Oncol. 2000;18:332-339.
29. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis. Blood. 2000;96:2399-2404.
30. Villela L, Lopez-Guillermo A, Montoto S, et al. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer. 2001;91:1557-1562.
31. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001;19:406-413.
32. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493-1498.
33. Nückel H, Dürig J, Dührsen U. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas. Ann Hematol. 2003;82:481-486.
34. Jagannath S, Velasquez WS, Tucker SL, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol. 1986;4:859-865.
35. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.